Profile data is unavailable for this security.
About the company
Demant A/S, formerly William Demant Holding A/S, is a Denmark-based company engaged in the healthcare industry. It develops, manufactures and sells products and equipment designed to aid the hearing and communication of individuals. The Group focuses on four business areas: Hearing Devices, including such brands as Bernafon, Oticon, Frontrow, Phonic Ear and Sonic; Hearing Implants, including Oticon Medical; Diagnostic Instruments, comprising operations of such audiometer companies as Interacoustics, Grason-Stadler, Amplivox, Maico and MedRx, and Personal Communication, which includes the business of Sennheiser Communications, a headset producer. The Company operates globally, through more than 90 subsidiaries and associates worldwide.
- Revenue in DKK (TTM)22.38bn
- Net income in DKK2.65bn
- Incorporated1983
- Employees21.50k
- LocationDemant A/SKongebakken 9SMOERUM 2765DenmarkDNK
- Phone+45 39177300
- Fax+45 39277900
- Websitehttps://www.demant.com/
More ▼
Mergers & acquisitions
| Acquired company | DEMANT:CPH since announced | Transaction value |
|---|---|---|
| Dansk HoreCenter A/S | -5.03% | 14.86m |
Data delayed at least 15 minutes, as of Nov 13 2024 14:44 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Embla Medical hf | 5.90bn | 484.93m | 15.01bn | 4.00k | 31.16 | 2.73 | 17.31 | 2.54 | 1.13 | 1.13 | 13.68 | 12.88 | 0.5755 | 2.23 | 6.65 | 1,475,355.00 | 4.75 | 4.06 | 5.51 | 4.76 | 62.02 | 62.47 | 8.25 | 6.91 | 1.26 | 6.59 | 0.4074 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Elekta AB (publ) | 11.67bn | 730.02m | 15.38bn | 4.57k | 21.86 | 2.31 | 10.34 | 1.32 | 2.96 | 2.96 | 47.38 | 28.01 | 0.5822 | 3.16 | 2.89 | 3,903,469.00 | 3.65 | 4.19 | 6.53 | 7.51 | 36.76 | 39.03 | 6.27 | 7.37 | 0.7425 | 3.91 | 0.4196 | 68.60 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
| Vitrolife AB | 2.29bn | -2.45bn | 20.74bn | 1.10k | -- | 2.45 | -- | 9.06 | -28.10 | -28.10 | 26.24 | 97.03 | 0.1867 | 3.48 | 6.48 | 3,293,791.00 | -19.99 | -4.57 | -20.71 | -4.78 | 58.16 | 58.38 | -107.03 | -21.89 | 2.36 | 9.24 | 0.135 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Ambu A/S | 5.39bn | 235.00m | 28.37bn | 5.20k | 136.61 | 5.75 | 30.48 | 5.26 | 0.8839 | 0.8839 | 20.26 | 21.00 | 0.7694 | 2.21 | 7.14 | 1,037,529.00 | 3.35 | 3.22 | 3.91 | 3.87 | 59.38 | 59.54 | 4.36 | 4.43 | 1.47 | 58.64 | 0.0907 | 25.41 | 12.90 | 13.84 | 39.88 | -5.81 | 2.06 | 0.00 |
| Getinge AB | 21.64bn | 1.09bn | 30.08bn | 11.85k | 29.59 | 1.65 | 12.69 | 1.39 | 6.21 | 6.21 | 123.33 | 111.09 | 0.5937 | 2.51 | 7.30 | 2,861,487.00 | 3.01 | 5.31 | 4.00 | 6.98 | 45.80 | 47.83 | 5.07 | 8.69 | 0.5965 | 10.34 | 0.2629 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| Sectra AB | 1.17bn | 288.16m | 33.47bn | 1.22k | 124.12 | 33.55 | 94.99 | 28.70 | 2.31 | 2.31 | 9.36 | 8.55 | 0.6136 | -- | 3.63 | 1,503,436.00 | 15.16 | 15.75 | 28.08 | 29.52 | 47.01 | 64.95 | 24.71 | 19.59 | -- | -- | 0.027 | 0.00 | 26.84 | 4.06 | 14.25 | 16.58 | 48.37 | -- |
| Demant A/S | 22.38bn | 2.65bn | 58.68bn | 21.50k | 22.15 | 6.12 | -- | 2.62 | 11.98 | 10.92 | 101.23 | 43.36 | 0.7192 | 2.03 | 5.68 | 1,034,778.00 | 8.52 | 8.27 | 11.68 | 13.23 | 75.45 | 74.14 | 11.85 | 11.34 | 1.06 | 5.58 | 0.6244 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Coloplast A/S | 27.03bn | 5.05bn | 190.61bn | 16.25k | 40.10 | 11.39 | 30.06 | 7.05 | 22.61 | 22.61 | 121.01 | 79.62 | 0.5618 | 2.44 | 6.01 | 1,663,692.00 | 10.50 | 16.21 | 14.49 | 22.91 | 67.59 | 67.85 | 18.69 | 21.02 | 0.6637 | 8.49 | 0.5578 | 92.23 | 10.33 | 8.54 | 5.62 | 5.46 | 14.30 | 5.29 |
Data as of Nov 13 2024. Currency figures normalised to Demant A/S's reporting currency: Danish Krone DKK
8.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Canada Pension Plan Investment Boardas of 31 Mar 2024 | 4.44m | 2.01% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 3.30m | 1.49% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.35m | 1.06% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 1.61m | 0.73% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 1.58m | 0.71% |
| BI Asset Management Fondsm�glerselskab A/Sas of 31 Aug 2024 | 1.47m | 0.66% |
| Carmignac UK Ltd.as of 30 Sep 2024 | 1.24m | 0.56% |
| Nykredit Bank A/S (Investment Management)as of 31 Oct 2024 | 1.21m | 0.55% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 1.13m | 0.51% |
| Geode Capital Management LLCas of 07 Nov 2024 | 1.04m | 0.47% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
